Access to Genetic Testing in Underserved Patients With Cancer (NCT06422455)
Increasing Access to Genetic Testing in Underserved Patients Using a Multilingual Conversational Agent
🩺 Plain-English Summary (8th-Grade Level)
This study compares the experiences of people who receive information about genetic testing from a computer-generated character to patients who receive information from a human genetics healthcare provider. Patients with cancer are increasingly recommended for genetic testing as standard of care. Multiple factors contribute to low usage of genetic testing but for many patients the lack of access to genetic counseling and testing is an important and flexible factor. Lack of access is especially relevant to racial/ethnic minority patients and those living in non-metropolitan rural settings who are frequently cared for at safety-net hospitals with limited genetics services. Alternative delivery models are necessary to improve rates of access to genetic testing in patients with cancer. Health information technology is under used by genetics providers. A patient-facing relational agent (PERLA) will provide pre-test genetics education in both English and Spanish across two clinical settings to facilitate more timely access to genetic testing. Using the PERLA intervention may help researchers learn different ways to provide education about genetic testing to patients with cancer compared to usual care.
Who can join: Review the eligibility criteria below.
Location: USC / Norris Comprehensive Cancer Center — Los Angeles, California
Age range: 18 Years
🧪 Interventions in This Study
- Best Practice (OTHER)
- Educational Intervention (OTHER)
- Electronic Health Record Review (OTHER)
- Genetic Counseling (OTHER)
- Interview (OTHER)
- Survey Administration (OTHER)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (2 Sites)
- USC / Norris Comprehensive Cancer Center — Los Angeles, California
- University of Rochester — Rochester, New York
📞 Contact the Study Coordinator
Phone: (323) 409-7710
Email: ricker@usc.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Breast Carcinoma
- Mobile Health for Adherence in Breast Cancer Patients — Fairbanks, Alaska
- An Investigational Surgical Procedure (Vascularized Lymph Node Transfer) in Reducing the Risk of Lymphedema in Patients With Breast Cancer Undergoing Breast Reconstruction — Houston, Texas
- Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer — Houston, Texas
- HOPE-Genomics Intervention for the Improvement of Cancer Patient Knowledge of Genomics — Duarte, California
- A Digital Health Intervention to Improve Symptoms and Physical Activity During Breast Radiation — Seattle, Washington
- Breast Cancer WEight Loss Study (BWEL Study) — Daphne, Alabama
Explore by condition: All Breast Carcinoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.